Media coverage about Neurocrine Biosciences (NASDAQ:NBIX) has been trending somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Neurocrine Biosciences earned a daily sentiment score of 0.11 on Accern’s scale. Accern also gave press coverage about the company an impact score of 44.9433608154135 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Several equities analysts have weighed in on NBIX shares. Robert W. Baird restated an “outperform” rating and set a $66.00 price target on shares of Neurocrine Biosciences in a report on Thursday, September 21st. Oppenheimer set a $85.00 target price on Neurocrine Biosciences and gave the company a “buy” rating in a research report on Tuesday, December 12th. Jefferies Group reaffirmed a “buy” rating and set a $69.00 target price (up from $66.00) on shares of Neurocrine Biosciences in a research report on Tuesday, October 3rd. Leerink Swann reiterated an “outperform” rating and issued a $83.00 price target (up from $72.00) on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Finally, Barclays boosted their target price on Neurocrine Biosciences from $75.00 to $85.00 and gave the stock an “overweight” rating in a research note on Thursday, November 2nd. One equities research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Neurocrine Biosciences presently has an average rating of “Buy” and an average target price of $78.88.
Shares of Neurocrine Biosciences (NASDAQ NBIX) traded up $2.20 during trading on Tuesday, reaching $77.59. The company had a trading volume of 926,400 shares, compared to its average volume of 1,087,172. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05. Neurocrine Biosciences has a 52 week low of $37.56 and a 52 week high of $78.05. The stock has a market capitalization of $6,866.17, a price-to-earnings ratio of -34.95 and a beta of 0.35.
Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Wednesday, November 1st. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.36. The company had revenue of $60.77 million during the quarter, compared to analyst estimates of $29.38 million. During the same quarter in the previous year, the business posted ($0.43) earnings per share. equities research analysts predict that Neurocrine Biosciences will post -1.66 earnings per share for the current fiscal year.
In related news, Director Gary A. Lyons sold 10,000 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $72.92, for a total transaction of $729,200.00. Following the transaction, the director now owns 272,066 shares of the company’s stock, valued at $19,839,052.72. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Darin Lippoldt sold 9,900 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $73.05, for a total transaction of $723,195.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 83,952 shares of company stock worth $6,145,915. Corporate insiders own 4.80% of the company’s stock.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.